WCG
VRTX icon

Weaver Consulting Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Weaver Consulting Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-26
Closed -$7K – 890
2020
Q3 		$7K Hold
26
– – ﹤0.01% 642
2020
Q2 		$8K Hold
26
– – ﹤0.01% 586
2020
Q1 		$6K Hold
26
– – ﹤0.01% 543
2019
Q4 		$4K Hold
26
– – ﹤0.01% 666
2019
Q3 		$4K Hold
26
– – ﹤0.01% 650
2019
Q2 		$5K Hold
26
– – ﹤0.01% 596
2019
Q1 		$4K Buy
+26
New +$4.8K ﹤0.01% 1179

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Weaver Consulting Group's VRTX Position: Q4 2020 in Review

Weaver Consulting Group sold out of Vertex Pharmaceuticals (VRTX) in Q4 2020, closing a stake of 26 shares — an estimated $7K sold.

Weaver Consulting Group first reported a position in VRTX in Q1 2019 and held it in 7 quarters. The position peaked at $8K in Q2 2020. 970 funds tracked by Wall St. Rank hold VRTX as of Q4 2020.

  • Weaver Consulting Group reported no remaining Vertex Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Weaver Consulting Group sold 26 Vertex Pharmaceuticals shares in Q4 2020, an estimated $7K.
  • Weaver Consulting Group first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 7 quarters.
  • Weaver Consulting Group's Vertex Pharmaceuticals position peaked at $8K in Q2 2020.
  • 970 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2020.

Based on Weaver Consulting Group's 13F filing for Q4 2020, filed 29 Jan 2021.